Cybin (CYBN) announced that it has received approval from the UK Medical and Healthcare Products Regulatory Agency to commence EMBRACE, the second pivotal study in Paradigm, the company’s Phase 3 multinational program evaluating CYB003, a proprietary deuterated psilocin analog. The company previously received Breakthrough Therapy Designation from the FDA for CYB003 for the adjunctive treatment of Major Depressive Disorder.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN:
- Cybin Inc. Expands Market Strategy with New SEC Filing
- Cybin Inc. Secures $50 Million in Convertible Debenture Deal
- Cybin’s Promising Clinical Progress and Strong Financial Position Justify Buy Rating
- Cybin price target lowered to $70 from $73 at Canaccord
- Cybin Inc. Reports on Governance and Compliance